ad26.rsv.pref
Vaccineexperimental
Clinical trial activity
18 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
15
Phase 3
9
Phase 4
1
Earliest trial started Nov 8, 2016 (NCT02926430)
Timeline
Indications
Approved for
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314975 ↗
Also known as
- ad26.rsv.pref
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06684743 | Phase 4 | Nov 30, 2024 | Pfizer, University of Copenhagen |
| NCT06593587 | Phase 3 | Oct 7, 2024 | Pfizer |
| NCT06325657 | Phase 3 | Mar 12, 2024 | Pfizer |
| NCT05327816 | Phase 1/Phase 2 (Phase 2) | Apr 13, 2022 | Janssen Pharmaceutica NV |
| NCT05301322 | Phase 3 | Apr 11, 2022 | Pfizer |
| NCT05242432 | Phase 3 | Apr 1, 2022 | Janssen Pharmaceutica NV |
| NCT05101486 | Phase 3 | Nov 1, 2021 | Janssen Pharmaceutica NV |
| NCT05083585 | Phase 3 | Oct 8, 2021 | Janssen Pharmaceutica NV |
| NCT05071313 | Phase 3 | Oct 4, 2021 | Janssen Pharmaceutica NV |
| NCT05070546 | Phase 3 | Sep 29, 2021 | Janssen Pharmaceutica NV |
| NCT04908683 | Phase 3 | Jul 21, 2021 | Janssen Pharmaceutica NV |
| NCT03795441 | Phase 1 | Jan 7, 2019 | Janssen Pharmaceutica NV |
| NCT03606512 | Phase 1/Phase 2 (Phase 2) | Dec 14, 2018 | Janssen Pharmaceutica NV |
| NCT03502707 | Phase 1/Phase 2 (Phase 2) | Jul 6, 2018 | Janssen Pharmaceutica NV |
| NCT03339713 | Phase 2 | Dec 7, 2017 | Janssen Pharmaceutica NV |
| NCT03303625 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2017 | Janssen Pharmaceutica NV |
| NCT03334695 | Phase 2 | Oct 16, 2017 | Janssen Pharmaceutica NV |
| NCT02926430 | Phase 1 | Nov 8, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 14 | 13 | 3 | 2016 |
| Pfizer | For profit | 4 | 3 | 2 | 2022 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2016 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1